Editas Medicine Inc (NASDAQ: EDIT) on Tuesday, plunged -2.98% from the previous trading day, before settling in for the closing price of $5.37. Within the past 52 weeks, EDIT’s price has moved between $5.11 and $11.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 101.57% over the past five years. The company achieved an average annual earnings per share of -27.84%. With a float of $81.24 million, this company’s outstanding shares have now reached $81.77 million.
Let’s look at the performance matrix of the company that is accounted for 265 employees.
Editas Medicine Inc (EDIT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Editas Medicine Inc is 1.21%, while institutional ownership is 77.74%. The most recent insider transaction that took place on Mar 05 ’24, was worth 732,884. In this transaction CEO of this company sold 77,824 shares at a rate of $9.42, taking the stock ownership to the 327,470 shares. Before that another transaction happened on Mar 04 ’24, when Company’s SVP, CHIEF MEDICAL OFFICER sold 20,327 for $9.42, making the entire transaction worth $191,425. This insider now owns 141,543 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -27.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Editas Medicine Inc (EDIT) is currently performing well based on its current performance indicators. A quick ratio of 5.39 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.06, a number that is poised to hit -0.63 in the next quarter and is forecasted to reach -2.73 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ: EDIT) saw its 5-day average volume 1.51 million, a negative change from its year-to-date volume of 1.81 million. As of the previous 9 days, the stock’s Stochastic %D was 22.29%. Additionally, its Average True Range was 0.34.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 1.52%, which indicates a significant decrease from 6.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.68% in the past 14 days, which was lower than the 68.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.42, while its 200-day Moving Average is $8.28. Nevertheless, the first resistance level for the watch stands at $5.31 in the near term. At $5.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.47. If the price goes on to break the first support level at $5.15, it is likely to go to the next support level at $5.10. Assuming the price breaks the second support level, the third support level stands at $4.99.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
Market capitalization of the company is 428.42 million based on 82,235K outstanding shares. Right now, sales total 78,120 K and income totals -153,220 K. The company made 60,050 K in profit during its latest quarter, and -18,870 K in sales during its previous quarter.
